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Abstract
Rationale:Thedevelopment of evidence-based treatment guidelines
for pediatric pulmonary arterial hypertension (PAH) is hampered by
lack of pediatric clinical trials. Trial design is hampered by lack of a
feasible clinical endpoint in this population.
Objectives: To evaluate the use of accelerometry for measuring
physical activity (PA) in pediatric PAH and to investigate its
correlation with clinical disease severity markers.
Methods:We included children from the Dutch National Network
for Pediatric Pulmonary Hypertension. Control patients were
recruited from the outpatient cardiology clinic of the Beatrix
Children’s Hospital. Children were asked to wear the accelerometer
for 7 days. Vectormagnitude counts perminute (VMCPM) and time
per day spent in different PA intensity levels were defined as
accelerometer outcomes.
Measurements and Main Results: VM CPM was lower in
childrenwith PAH (n = 29) than in controls (n = 60; 647 vs. 921; P,
0.001). Children with PAH spent less time in moderate and vigorous
PA (13 vs. 29min/d and2 vs. 13min/d, respectively;P, 0.001). Time
spent in moderate and vigorous PA correlated inversely with World
Health Organization functional class. Time spent in moderate PA
correlated positively with 6-minute-walk distance. In post hoc
analyses, VM CPM and time spent in moderate/vigorous combined
and vigorous PA were associated with outcome (P< 0.044).
Conclusions: PA is markedly decreased in children with PAH.
Accelerometer output correlated with clinical disease severity markers
and may predict outcome. We showed an exciting potential of PA as a
meaningful endpoint for clinical trials in pediatric PAH, although its
clinical utility and prognostic value need to be further validated.
Keywords: pulmonary arterial hypertension; pediatrics; physical
activity; accelerometry
Pulmonary arterial hypertension (PAH) is a
rare, progressive disease of the small
pulmonary arteries and has a poor
prognosis. Randomized controlled trials
(RCTs) have led to significant advances
and the development of treatment
guidelines for adult PAH, resulting in
improved quality of life and survival in
adults with PAH (1).
In pediatric PAH, however, such
advances are delayed, and prognosis
remains unfavorable (2–5). In the United
States, none, and in Europe only one, of the
currently available PAH-targeted drugs are
approved for children. The development of
evidence-based treatment guidelines is
hampered by the lack of RCTs in the
pediatric age group. One essential problem
in the design of RCTs in pediatric PAH is
the definition of validated clinically
meaningful endpoints or surrogate
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endpoints applicable in the pediatric age
spectrum (6). Death may be considered a
robust endpoint, as improving survival is a
main objective in the treatment of PAH.
However, such an endpoint is associated
with significant ethical and practical
problems (including the need for long study
duration and large sample size). Given the
rareness and poor prognosis of (pediatric)
PAH, mortality trials are neither feasible
nor preferable (7, 8).
In adults, the 6-minute-walk distance
(6MWD) has served as primary endpoint in
most pivotal clinical trials evaluating the
efficacy of PAH-targeted drugs (9–11). In
children, its use has been debated because
the test cannot be reliably performed in
young children or in children with
developmental delays. Currently reported
data on the value of the 6MWD in pediatric
PAH regarding the assessment of disease
severity and prognosis are contradictory,
which seems related to the selection of
children (2, 12–14). To date, no validated
endpoints are available in young children
with PAH, and therefore this is a high
unmet need.
Accelerometry has been proposed as a
potential endpoint in pediatric PAH, also
because of its feasibility in young children
(8, 15). It has been frequently used to
measure physical activity (PA) in numerous
clinical settings in both adults and children,
including various cardiopulmonary
diseases, and has been shown to correlate
with peak oxygen consumption (16–19).
Recently, accelerometer output has been
reported to correlate with measurements of
exercise tolerance in adult patients with
PAH (20, 21).
To date, data regarding PA measured
by accelerometry in children with PAH are
lacking. In this study, we evaluated the value
of accelerometry in pediatric PAH by
comparing PA measured by accelerometry
in children with PAH with that in healthy
controls. Furthermore, we assessed whether
accelerometer output correlates with disease
severity and outcome in children with PAH.
Methods
This is a prospective, observational study
within the Dutch National Network for
Pediatric Pulmonary Hypertension (22) and
controls. The Medical Ethics Review Board
of the University Medical Center
Groningen waived the need for ethical
approval. All subjects and/or their
guardians gave written informed consent.
In all included patients, PAH had been
confirmed with cardiac catheterization, and
patients were classified according to the
Updated Clinical Classification of PAH,
Nice, France, 2013 (23, 24).
Patients and Controls
Children with PAH who visited the
outpatient clinic of the National Referral
Center for Pulmonary Hypertension in
Childhood between June 2013 and March
2016 were asked to wear the ActiGraph
wGT3X accelerometer (Pensacola, FL).
Children with muscular diseases were
excluded.
Patient characteristics, World Health
Organization Functional Class (WHO-FC),
6MWD (in children >7 yr of age), and
serum levels of N-terminal pro brain
natriuretic peptide (NT-proBNP) were
assessed. The 6-minute-walk test was
conducted as previously reported (12, 25).
6MWD was presented as both absolute
values and percentage of predicted (26).
In one child with spondyloepiphyseal
dysplasia, the 6-minute-walk test was
regarded as unreliable, and therefore the
test result was not used in the analyses.
Data on medication use were also collected:
calcium channel blocker therapy or PAH-
targeted mono-, dual, or triple therapy.
For every child with PAH, two controls
matched by age and sex were recruited from
children who visited the outpatient pediatric
cardiology clinic of the Beatrix Children’s
Hospital for screening for cardiac diseases
but who appeared to have no, or no
hemodynamically relevant, cardiac disease.
Accelerometry
Children were instructed to wear the
accelerometer for 7 consecutive days on the
right hip during all awake time, except for
during water-related activities. The
accelerometer was programmed to record
triaxial data at a frequency of 60 Hz. Data
were processed using the ActiLife software
(ActiGraph). Data were downloaded and
integrated into 15-second epochs. Nonwear
periods were defined as consecutive zeroes
for >90 minutes, with a two-spike
tolerance (27). Days with >8 hours of
accelerometer wear were considered valid.
In infants who still slept during the day,
and consequently were awake for only 6–8
hours, days with >6 hours of accelerometer
wear were considered valid. For inclusion
in the analyses, patients were required to
have >4 valid days.
Vector magnitude (VM) counts per
minute (CPM) was defined as the primary
accelerometer outcome. The VM is the
square root of the quadrate of the
three separate dimensional axes
[ðx2 1 y2 1 z2Þ1=2]. The total accelerometer
VM counts were divided by the total
number of minutes the device was worn
to calculate VM CPM. PA intensity was
defined as secondary accelerometer
outcome and classified into sedentary,
light, moderate, and vigorous PA, using
cutpoints for the vertical axis as defined by
Evenson and colleagues (28, 29).
Statistics
Data are presented as mean (SD), median
(interquartile range), or number
(percentage). Statistical analysis was
At a Glance Commentary
Scientific Knowledge on the
Subject: To date, the development of
treatment guidelines for pediatric
pulmonary arterial hypertension
(PAH) guided by evidence-based
treatment efficacy is hampered by the
virtual lack of randomized controlled
trials (RCTs) in this population. A
major reason for this lack is the
difficulty of defining a clinically
meaningful and validated endpoint in
infants and young children with PAH.
Accelerometer output has been
proposed as a potential endpoint in
pediatric PAH, but data on the value of
accelerometry in pediatric PAH are
currently unavailable.
What This Study Adds to the
Field: This study shows that physical
activity measured by accelerometry is
markedly decreased in children with
PAH compared with in healthy control
patients. Furthermore, accelerometer
output correlated with clinical markers
of disease severity and may also predict
outcome. Accelerometer output
directly reflects how a patient functions
and could serve as a clinically
meaningful endpoint in RCTs for
pediatric PAH. Further validation in a
second, larger population of children
with PAH is warranted.
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conducted using IBM SPSS 22.0 (Armonk,
NY) and R package (for partial Spearman
correlation coefficients). Independent
Student’s t test, Mann-Whitney U test,
chi-square test, or Fisher’s exact test were
used to compare data, as appropriate.
Pearson and Spearman correlation
coefficients and linear regression analysis
were used to evaluate the association
between accelerometer output and clinical
disease severity markers. For the sake of
clinical interpretation, WHO-FC was taken
as continuous variable in the linear
regression analyses. Log-10 transformation
was performed for serum levels of
NT-proBNP to achieve normality. For the
sake of clinical interpretation, log-2
transformation was performed for
combined moderate/vigorous, moderate,
and vigorous PA to achieve normality.
In post hoc outcome analyses, the first
occurrence of death, lung transplantation, or
nonelective PAH-related hospitalization
was defined as the primary endpoint.
Otherwise, children were censored at May 1,
2016. Freedom from events was depicted
using a Kaplan-Meier curve. To explore
whether accelerometer output predicted
outcome, Cox regression analysis was
performed.
P values of ,0.05 were considered
significant.
Results
Children with PAH
In total, 30 children with PAH were asked to
wear an accelerometer. One 7-year-old child
with Down syndrome refused to wear the
accelerometer and was therefore excluded
from the study.
Patient and disease characteristics of
the remaining 29 children are shown in
Table 1. There was a female predominance,
and median age at diagnosis was 3.1 years.
Median time between diagnosis and
accelerometer study was 2.9 years
(interquartile range, 0.9–11.7 yr). Four
children (14%) were ,5 years of age at the
time of accelerometer study. Eight children
(28%) wore the accelerometer within 1 year
after diagnosis. Eleven children had
idiopathic or hereditary PAH, 17 had PAH
associated with congenital heart disease,
and one had PAH associated with
connective tissue disease. Three children
had Down syndrome. Most children were
in WHO-FC II or III. 6MWD was available
in 19 children and not available in 9
children because of young age (,7 yr;
n = 7) or developmental disorders (n = 2).
Two children received calcium channel
blocker therapy, and the remaining
children received PAH-targeted therapies:
eight monotherapy, 15 dual therapy, and
five triple therapy.
Sixty age- and sex-matched controls
were included in the study (Table 2).
Controls visited the outpatient pediatric
cardiology clinic for evaluation of a cardiac
murmur, palpitations, or cardiac screening
in the context of familial history of
cardiomyopathy or arrhythmia.
Hemodynamic significant heart diseases
were excluded in all. Diagnoses included no
cardiac abnormality (n = 57), trivial valve
abnormalities (n = 1), and hemodynamic
irrelevant shunt defects (small ventricular
septal defect [n = 1] and mini silent patent
ductus arteriosus [n = 1]).
Table 1. Patient and Disease Characteristics of the Children with PAH
Characteristics All Children with PAH (N = 29)
Age of diagnosis, yr 3.1 (1.2–9.7)
Female 19 (66)
Down syndrome 3 (10)
Diagnosis
IPAH/HPAH 11 (38)
PAH-CHD 17 (59)
PAH-CTD 1 (3)
WHO-FC
I 4 (14)
II 15 (52)
III 9 (31)
IV 1 (3)
6MWD*, m; %pred* 4116 68; 61.66 10.0
NT-proBNP, ng/L† 160 (92–350)
PAH therapy
CCB monotherapy 2 (7)
PAH-targeted monotherapy 8 (27)
PAH-targeted dual therapy 15 (50)
PAH-targeted triple therapy 5 (17)
Definition of abbreviations: %pred = percentage of predicted; 6MWD = 6-minute-walk distance;
CCB = calcium channel blocker; IPAH/HPAH = idiopathic or hereditary pulmonary arterial
hypertension; NT-proBNP = N-terminal pro brain natriuretic peptide; PAH = pulmonary arterial
hypertension; PAH-CHD = pulmonary arterial hypertension associated with congenital heart
disease; PAH-CTD = pulmonary arterial hypertension associated with connective tissue disease;
WHO-FC =World Health Organization Functional Class.
Data are presented as median (interquartile range), number (percentage), or mean6 SD, as
appropriate.
*6MWD available for 19 children.
†NT-proBNP available for 28 children.
Table 2. Physical Activity of Children with PAH and Controls
Characteristics Children with PAH (n = 29) Controls (n = 60) P Value
Age at test, yr 12.0 (7.5–14.7) 11.8 (9.0–15.1) 0.878
Female 19 (66) 38 (63) 0.841
BMI, kg/m2 17.26 2.6 18.06 3.0 0.249
VM CPM 6476 274 9216 309 ,0.001
Time in sedentary PA, h/d 8.76 2.0 8.36 1.7 0.317
Time in light PA, h/d 3.56 1.3 3.86 0.9 0.250
Time in MVPA, min/d 13.3 (7.5–25.0) 41.3 (31.9–54.9) ,0.001
Time in moderate PA, min/d 12.5 (4.8–20.9) 29.2 (21.1–38.5) ,0.001
Time in vigorous PA, min/d 2.1 (0.8–4.4) 13.4 (7.9–19.4) ,0.001
Definition of abbreviations: BMI = body mass index; MVPA = combined moderate/vigorous physical
activity; PA = physical activity; PAH = pulmonary arterial hypertension; VM CPM= vector magnitude
counts per minute.
Data presented as median (interquartile range), number (percentage), or mean6 SD, as appropriate.
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Physical Activity in Children with PAH
and Controls
All included children wore the
accelerometer for >4 valid days and were
included in the PA analyses. The majority
of these children (89%) had 6 or 7 valid
days, which did not differ between children
with PAH and controls (P = 0.642). Mean
wear time per valid day was 12.56 1.7
hours for children with PAH and 12.86
1.1 hours for controls (P = 0.318). There
was no significant day-to-day variance in
VM CPM (paired-samples t tests; P> 0.094).
During the weekend, children wore the
accelerometer for a shorter time per day
compared with weekdays (12.06 1.6 vs.
13.06 1.4 h/d; P, 0.001). However, no
significant difference in VM CPM during
week- or weekend days could be demonstrated
(paired-samples t test; P= 0.641).
Mean VM CPM was significantly lower
in the children with PAH compared with in
controls (Table 2 and Figure 1).
Furthermore, children with PAH spent
significantly less time per day in both
moderate and vigorous activities compared
with controls (Table 2 and Figure 2).
Accelerometer Output in Pediatric
PAH
Mean VM CPM did not differ between the
3 children with and the 26 children without
Down syndrome (733 vs. 638; P = 0.574).
There was a significant correlation
between age and VM CPM (r =20.495;
P = 0.006), and a considerably stronger
correlation between age and time spent in
sedentary (r = 0.764; P , 0.001) and light
(r =20.466; P = 0.011) PA. Time spent in
moderate, vigorous, and combined
moderate/vigorous PA did not correlate
with age (data not shown). Children with
associated PAH spent less time in vigorous
PA than children with idiopathic PAH
(IPAH; r =20.421; P = 0.023 [reference
category IPAH]). We could not
demonstrate a correlation between
accelerometer output and sex, body mass
index, diagnosis, or NT-proBNP serum
level (data not shown).
VM CPM correlated inversely with
WHO-FC in the univariate analysis, but lost
its significance when corrected for age
and diagnosis (Table 3) Time spent in
moderate, vigorous, and combined
moderate/vigorous PA correlated inversely
with WHO-FC, which did not change
substantially after adjustment for age and
diagnosis. Time spent in moderate,
vigorous, and combined moderate/vigorous
PA correlated positively with 6MWD,
although with respect to time spent in
vigorous PA, statistical significance did
not remain after adjustment for age and
diagnosis. We also tested for differences
in regression coefficients between
accelerometer outcomes and clinical disease
severity markers in a univariate analysis
and analysis adjusted for age and
diagnosis (Table 4). The findings
remained generally the same. In addition,
similar correlation and regression
coefficients were observed between the
percentage of predicted 6MWD and time
spent in moderate, vigorous, and combined
moderate/vigorous PA.
Outcome
During a median follow-up of 2.2 years, 3
children were nonelectively hospitalized for
PAH-related reasons (i.e., progressive right
heart failure). Two children subsequently
died within weeks after admission. In none
of the 29 children was intravenous or
subcutaneous prostacyclin therapy
initiated during the study period.
Post hoc Cox regression analysis
revealed that lower VM CPM was
significantly associated with a shorter time
to event (Figure 3). Also, less time spent in
more intense activity levels (combined
moderate/vigorous PA or vigorous PA) was
associated with worse outcome (P = 0.036
and P = 0.044, respectively).
Discussion
This study is the first to demonstrate that PA
measured by accelerometry is markedly
decreased in children with PAH compared
with controls, particularly moderate and
vigorous PA. Furthermore, accelerometer
output correlated considerably with clinical
disease severity markers and outcome.
Accelerometry in Pediatric PAH
In pediatric PAH, there is a high unmet need
for an endpoint or a validated surrogate
endpoint applicable in the pediatric age
spectrum. A clinically meaningful endpoint
should reflect how a patient feels, functions,
or survives (30). Function refers to the
ability of a patient to carry out normal daily
activities. This is especially important in
PAH, as exercise intolerance, reflected by
dyspnea at exertion, increased WHO-FC,
and impaired 6MWD and peak oxygen
consumption, is one of the main features of
PAH (1, 5, 23, 31). Children with PAH
cannot keep up with their peers in
participating in the normal daily activities
of childhood, such as playing in the
playground, running, dancing, or playing
soccer, which greatly affects quality of life.
In this study, we used accelerometry to
objectively measure PA, and confirmed that
PA is significantly decreased in children
with PAH. As such, accelerometer output
provides direct information on how a child
with PAH functions. In this respect,
accelerometer output is thus not a surrogate
endpoint, with inherently required
validation criteria, but constitutes a
clinically meaningful endpoint.
Impaired exercise tolerance in PAH has
been usually evaluated using 6MWD.
Recently, a study in the Dutch cohort of
pediatric patients with PAH showed that the
6MWD is an independent predictor of
prognosis in children >7 years of age and
reflects disease severity and exercise
tolerance in daily life (12). The current
study demonstrates that accelerometer
output correlates with 6MWD, confirming
the clinical relevance of this measurement.
This correlation has also been reported
in adults with PAH (20, 21). A well-
established limitation of the 6-minute-
walk test is that it cannot be reliably
performed in young children or in children
with severe mental or physical disabilities.
Furthermore, it can be influenced by non-
PAH-related factors such as motivation of
the child and guidance during the test.
In contrast, accelerometry provides an
objective measurement of PA and can be
reliably performed in children of all ages,
regardless of any disabilities. Therefore,
400
Children with PAH Controls
P<0.001
0
800
1200
V
M
 C
P
M
1600
Figure 1. Vector magnitude counts per minute
(VM CPM) for the children with pulmonary arterial
hypertension (PAH) and controls. Showing all
individual data for each group with mean and
SD. Mean VM CPM was significantly lower in the
children with PAH compared with controls (647
vs. 921 CPM, respectively; P, 0.001).
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accelerometry could be a good alternative
to evaluate exercise tolerance in children
who cannot (reliably) perform a 6-minute-
walk test.
Another well-established clinical
parameter for disease severity is the WHO-
FC, a subjective assessment of a patient’s
clinical condition using the occurrence of
symptoms at different levels of PA. Its value
in infants and young children has been
debated, as it is based on the observation
and impression of caregivers and/or the
treating physician. Nevertheless, WHO-FC
also has been shown to be a strong and
independent predictor of prognosis in
pediatric PAH (13, 32). In addition,
changes in WHO-FC were recently shown
to predict survival (33). In this study,
accelerometer output correlated with
WHO-FC, which further supports the value
of accelerometry in assessing exercise
tolerance in pediatric PAH.
In this cross-sectional study,
accelerometer output did not correlate with
single time-point measurements of NT-
proBNP serum level. Although single time-
point measurements of NT-proBNP have
been shown to predict outcome in pediatric
PAH, its major strength is that changes in
NT-proBNP serum levels during follow-up
predict (changes in) outcome (33). As such,
NT-proBNP qualifies as a surrogate
endpoint and may serve as a treatment goal
in pediatric PAH. Accelerometer output,
however, reflecting how a patient feels
and functions, constitutes a clinically
meaningful endpoint in itself. Although
both measurements are affected by the
disease PAH, and both may predict
outcome in pediatric PAH, they represent
two different features of PAH, that is,
myocardial load versus stamina, and it is
not clear whether the mechanisms by which
both measurements are affected by the
disease are the same. This also accounts for
other proposed endpoints, including
biomarkers, echocardiographic parameters,
and hemodynamics. Therefore, the absence
of a one-on-one correlation between
accelerometer output and such endpoints
does not diminish the value of either of
them, nor of accelerometry as a clinically
meaningful endpoint in pediatric PAH.
Further research is needed to establish
whether changes in NT-proBNP serum
levels over time correlate with changes in
accelerometer output.
A major advantage of accelerometry
over these other proposed endpoints is that
it is a direct, objective, noninvasive, and
relatively cheap measurement. Furthermore,
accelerometry appeared to be feasible in
children of all ages. Of 30 children, in only
one child with Down syndrome did
accelerometry appear not feasible, as a
result of noncompliance. Biomarkers,
echocardiographic parameters, and
hemodynamics do not directly reflect how a
patient feels, functions, or survives.
However, these measurements may carry
prognostic value and could qualify as
surrogates for outcome (7, 34). To date,
their use as surrogates remains to be
validated. In addition, the assessment of
hemodynamics requires the need for
invasive measurement, as these are
obtained during cardiac catheterization,
bringing along certain risks, and often the
need for sedation or anesthesia (35, 36).
In a post hoc analysis, accelerometer
output predicted outcome, defined as the
first occurrence of death, lung
transplantation, or hospitalization. It must
be noted that only three events occurred,
and all consisted of nonelective PAH-related
hospitalizations. Reason for hospitalization
was progressive right heart failure, and
two children died within weeks after
hospitalization. Although these results
suggest that accelerometer output is of
prognostic value in pediatric PAH, this
study does not allow for definitive
conclusions in this respect. Further research
is needed to further establish the value of
accelerometry as a prognostic tool.
PA in Children with PAH
There may be various explanations for the
markedly decreased PA in children with
PAH. First, the PAH itself, resulting in
decreased cardiac output, could very well
cause exercise intolerance, resulting in
decreased PA. Children with associated
Time spent in:
Sedentary PA
Light PA
MVPA*
Moderate PA*
Vigorous PA*
0 10 20 30
Minutes
Hours
0 2 4 6 8 10
40
* p<0.001
PAH
Controls
50
Figure 2. Physical activity (PA) intensity levels for the children with pulmonary arterial hypertension
(PAH) and controls. Showing mean and SDs of hours per day spent in sedentary and light PA and
median minutes per day spent in moderate/vigorous PA (interquartile range for children with PAH,
7.5–25.0; for controls, 31.9–54.9), moderate PA (interquartile range for children with PAH, 4.8–20.9;
for controls, 21.1–38.5), and vigorous PA (interquartile range for children with PAH, 0.8–4.4; for controls,
7.9–19.4) for the children with PAH and controls. *P,0.001. MVPA=moderate/vigorous physical activity.
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PAH spent even less time in vigorous PA
than children with IPAH. This group mostly
included children with PAH associated with
congenital heart disease and shunt defects
(n = 14). Such children may not be able to
reach a vigorous PA intensity level because
of cyanosis that develops or aggravates
during exercise. Second, it may be that PA
is restricted by the caregivers/parents (or
the children with PAH themselves) because
of concerns and fear for adverse effects of
PA, such as dyspnea, syncope, or sudden
death. Chronic restriction of PA will lead to
decreased fitness and decreased muscle
strength. The latter was recently shown in
adult patients with PAH (37). Such fears
might have been enhanced by the fact that
exercise training (i.e., moderate or vigorous
PA) has long been believed to be harmful in
patients with PAH (38). However, this
point of view is changing, and with the
improved therapeutic options for PAH,
exercise training is now regarded to be safe
(1). Moreover, several studies in adults with
PH showed that exercise training improved
exercise capacity, 6MWD, WHO-FC,
quality of life, and peak oxygen
consumption and led to higher levels of
PA (measured by questionnaires) and
decreased levels of fatigue (39–41). Future
research, aiming at improving quality of
life, could be directed toward evaluating
muscle strength and the value of exercise
programs also in pediatric PAH.
Accelerometry could be used as a tool to
guide such programs and monitor efficacy.
Strengths, Limitations, and Future
Directions
As validated endpoints are currently lacking
in pediatric PAH, the results of this
proof-of-concept study form an important
base for the validation of accelerometer
output as a clinically meaningful endpoint.
Nevertheless, further validation of this
potentially valuable endpoint is warranted.
Its use should be evaluated in a second,
larger cohort, preferably including a larger
proportion of children ,5 years of age and
infants. Accelerometry has been previously
validated in young children in other
conditions, supporting its use also in the
very young ones (18). A potential
disadvantage of the use of accelerometry in
infants children may be that accelerometry
cannot recognize when a child is carried by
a caregiver. The use of diaries may
overcome this limitation. The age
distribution in our cohort, with
predominantly patients older than 5 years
of age, did allow for comparisons between
accelerometer output and 6MWD.
Further aspects that need to be
addressed to validate the use of
accelerometry in pediatric PAH include
investigating how PA levels measured by
accelerometry change over time in this
population, whether therapy effects can
be detected, and the determination of a
minimal clinically important change in
PA. With respect to reproducibility, the
Table 3. Correlations of Clinical Disease Severity Markers and Accelerometer Output
WHO Functional Class 6MWD
Univariate Adjusted for Age and Diagnosis Univariate Adjusted for Age and Diagnosis
r P Value r P Value r P Value r P Value
VM CPM 20.369 0.049 20.266 0.233 0.221 0.363
Sedentary PA 0.269 0.119 0.002 0.993
Light PA 20.282 0.138 0.282 0.242
MVPA 20.398 0.002 20.380 0.053 0.521 0.022 0.429 0.085
Moderate PA 20.371 0.048 20.356 0.085 0.585 0.009 0.530 0.029
Vigorous PA 20.466 0.015 20.445 0.022 0.456 0.050 0.317 0.215
Definition of abbreviations: 6MWD= 6-minute-walk distance; MVPA = combined moderate/vigorous physical activity; PA = physical activity;
VM CPM= vector magnitude counts per minute; WHO=World Health Organization.
Table 4. Regression Coefficients of Accelerometer Outcomes and Clinical Disease
Severity Markers
Predictive Value
Univariable Adjusted for Age and Diagnosis
B (95% CI) P Value B (95% CI) P Value
VM CPM
WHO-FC 20.1 (20.2 to 0.0) 0.065 20.1 (20.2 to 0.1) 0.314
6MWD, m 6 (28 to 21) 0.363 7 (212 to 26) 0.442
Sedentary PA, h/d
WHO-FC 0.1 (0.0 to 0.2) 0.121 0.0 (20.2 to 0.2) 0.771
6MWD, m 0 (218 to 19) 0.993 3 (223 to 28) 0.835
Light PA, h/d
WHO-FC 20.2 (20.4 to 0.0) 0.075 20.12 (20.4 to 0.1) 0.229
6MWD, m 17 (213 to 48) 0.242 32 (0 to 64) 0.050
MVPA, min/d
WHO-FC 20.2 (20.4 to 0.0) 0.038 20.2 (20.4 to 0.0) 0.040
6MWD, m 24 (4 to 44) 0.022 20 (23 to 44) 0.085
Moderate PA, min/d
WHO-FC 20.2 (20.4 to 0.02) 0.047 20.2 (20.4 to 0.0) 0.062
6MWD, m 29 (8 to 49) 0.009 26 (3 to 48) 0.029
Vigorous PA, min/d
WHO-FC 20.2 (20.3 to 0.0) 0.038 20.2 (20.3 to 0.0) 0.026
6MWD, m 17 (0 to 34) 0.050 13 (29 to 35) 0.215
Definition of abbreviations: 6MWD= 6-minute-walk distance; CI = confidence interval;
MVPA = combined moderate/vigorous physical activity; PA = physical activity; VM CPM= vector
magnitude counts per minute; WHO-FC=World Health Organization Functional Class.
B represents the increase or decrease in WHO-FC or 6MWD per 100 increase in VM CPM, hours per
day spent in sedentary and light PA, and per doubling of minutes per day spent in MVPA, moderate
PA, and vigorous PA.
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accelerometer device used in the current
study has been shown to have a good
reproducibility in children, including in
preschool children (42, 43). Although in the
current study accelerometer output did not
differ between weekdays and weekend days,
it has been suggested that children are less
active in the weekends than during
weekdays (44). Also, there may be seasonal
variation in children’s physical activity (45).
These remain topics for further
investigation.
The children with PAH included in this
study come from a national cohort with
standardized diagnostic, follow-up, and
treatment protocols. The inclusion of a
matched control group provided the
opportunity to directly compare PA between
children with PAH and children without
PAH. Complete and standardized follow-up
in all children further enhanced the power of
this study. In this study, we used the Evenson
cutpoints for PA intensity levels, currently
recommended to be used in children and
adolescents (29). General consensus on such
cutpoints is still to be achieved. The relatively
small sample size is a limitation of this study,
but is inherent to prospective studies in a rare
disease as pediatric PAH.
Conclusions
PA can be assessed objectively in children of
various ages using accelerometry. Children
with PAH have markedly decreased PA
compared with healthy controls. In
particular, time spent in higher PA intensity
levels was severely reduced. Accelerometer
output is associated with clinical disease
severity independent from age and
diagnosis and may also predict outcome.
It provides an objective and direct
measurement of how a patient functions.
Therefore, accelerometer output could serve
as a clinically meaningful endpoint for
clinical trials in children with PAH. Further
validation in a second, larger population of
children with PAH is warranted. n
Author disclosures are available with the text
of this article at www.atsjournals.org.
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